Cost-effective screening and treatment of Hepatitis C
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Issue brief (Leonard Davis Institute of Health Economics)
- Author(s):
- Weiner, Janet, author Linas, Benjamin, author
- Contributor(s):
- Leonard Davis Institute of Health Economics, issuing body. Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, issuing body.
- Publication:
- Philadelphia, PA : Leonard Davis Institute of Health Economics, September 2018
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Cost-Benefit Analysis Hepatitis C -- diagnosis Mass Screening -- economics Eligibility Determination Health Policy Hepatitis C -- drug therapy Insurance Coverage -- economics Mass Screening -- trends Medicaid -- economics Sofosbuvir -- economics Sofosbuvir -- therapeutic use Practice Guidelines as Topic Humans United States Centers for Disease Control and Prevention (U.S.)
- Genre(s):
- Technical Report
- Abstract:
- In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily cured by a short course of medication. Medical breakthroughs have now created the possibility of eliminating the transmission of HCV, but also bring a new challenge for the health system--how to identify individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the case for universal, one-time HCV screening for all US adults.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (7 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101735705 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101735705